Immunotherapy for Treating Age-Related Macular Degeneration
Case ID:
Neufeld 2007-161
Web Published:
10/14/2019
NU 2007-161B
Inventors
Arthur Neufeld*
Ai Ling Wang
Abstract
Deposition of drusen, accumulations of extracellular material, in the macula is a key factor in the etiology of Age-related Macular Degeneration (AMD). Northwestern researchers have identified compounds for the treatment and prevention of drusen. The researchers use an immunotherapeutic approach, targeting antibodies to intracellular proteins that contribute to the formation of these deposits upon becoming extracellular. The antigen/antibody response mechanism removes these proteins from the eye, decreasing the formation of drusen. This technology offers a novel therapeutic treatment for Age-related Macular Degeneration.
Applications
- Therapy for and prevention of AMD
Advantages
- Effective induction of immune response
- Treatment at various stages of AMD, addressing etiology or existing condition
IP Status
Issued US Patent No. 9,044,419
Patent Information:
| Title |
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
Categories:
Life Sciences > Therapeutics
Keywords:
Antibody
Ophthalmic disease
Therapeutics